96MO Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer (TNBC): A non-inferiority meta-analysis
Fabio Girardi(London School of Hygiene & Tropical Medicine), Valentina Guarneri(Istituto Oncologico Veneto), Federica Miglietta(University of Padua), Daniela Iannaccone(University of Padua), C. Barbieri(Istituto Oncologico Veneto), Tommaso Giarratano(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Anna Chiara Cattelan(Istituto Oncologico Veneto), C. Zurlo(University of Padua)
Cited by 0
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Sustainable care for children with cancer: a Lancet Oncology Commission
|The Lancet Oncology|2020|346
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290